Comments
Drug firm Lupin today said it has received attestation from the European Directorate for the Quality of Medicines (EDQM) for its Mandideep facility in Madhya Pradesh. The unit was inspected by EDQM in March this year, Lupin said in a statement.
“The inspection was focused on the application for certificate of suitability for the dossier of Cefaclor, along with facility inspection for Quality Management Systems based on cGMP, as laid under European Union rules governing medicinal products,” it added.
Lupin MD Nilesh Gupta said: “We are happy to receive the EDQM attestation for our Mandideep facility.” Over the past few months, Lupin has continued to drive multiple initiatives to further strengthen manufacturing standards and best practices to be amongst the best, he added.
The Lupin stock was trading 1.53 per cent up at Rs 827.90 on BSE in the afternoon.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.